Glenmark PMS Study interim data supports favipiravir safety, effectiveness

Published On 2021-06-09 04:30 GMT   |   Update On 2021-06-09 13:15 GMT
Advertisement

Mumbai: Pharma major, Glenmark Pharmaceuticals, has recently announced interim data of 503 patients from its Post Marketing Surveillance (PMS) study on Favipiravir in India.

The PMS study commenced in July 2020 aimed to evaluate safety and efficacy of Favipiravir in mild to moderate Covid-19 patients. This PMS is the first and large post marketing study being conducted in India on Favipiravir in mild to moderate Covid-19 patients and as on date, a total of 1083 patients have been enrolled in the prospective, open label, multicenter, single arm study. A total of 13 sites – both Government and private institutions – across Mumbai, Bangalore, Hyderabad, Nashik, Nagpur, and Trivandrum took part.

Advertisement

Interim data presented by Glenmark to the regulator reveals no new safety signals or concerns with the use of Favipiravir and already-known side effects such as weakness, gastritis, diarrhoea, vomiting etc., which were found to be mild in nature. The time to fever resolution was seen on day 3, while two-third of the patients achieved clinical cure on day 7. The study was conducted in patients with mild to moderate COVID-19, in line with the approved indication of the drug. The mean age of patients was 40 years, with the most common age group being 30-45 years. Women comprised 40%, while men 60% of the study population. Hypertension and Diabetes were the two most common comorbidities noted in these patients. Fever was present in all patients at baseline followed by cough (84.6%), fatigue (55%), new loss of taste (38.1%).

Commenting on these findings, Mr. Alok Malik, Group Vice President & Head, India Formulations, said, "It is encouraging to note that our interim data supports the safety and effectiveness of FabiFlu in real-world settings. Since its launch last year, FabiFlu has provided immense relief to millions of patients in India and the world, while also reducing the overall burden on healthcare infrastructure. We will soon submit the final study findings to the regulator and continue to deliver FabiFlu's multiple benefits to patients all over."



Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News